Brief: Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit
21/10/2026 02:38
BRIEF-Hutchmed (China) Closes Exclusive Development And License Agreement With GSK Unit Oct 21 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
CLOSES EXCLUSIVE DEVELOPMENT AND LICENSE AGREEMENT WITH GSK SUBSIDIARY
TO RECEIVE USD$110 MILLION UPFRONT AND UP TO USD$1.19 BILLION IN MILESTONE PAYMENTS
GSK SUBSIDIARY GRANTED WORLDWIDE RIGHTS TO HMPL-A830 EXCLUDING CHINA, HK, MACAU, TAIWAN
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation